Table 3.

Changes in outcomes from baseline to 6-mo follow-up (n = 195) [median (IQR)/mean ± SD]

Outcomes	Groups	Assessments, baseline	1 mo	3 mo	6 mo	% of improvement	χ2	P valuea	Significant pairs (post hoc)
Self-esteem	Experimental (n = 97)	20 (16.50-23); 20.05 ± 4.22	22 (18.50-24.50); 21.67 ± 4.08	23 (20-26); 22.76 ± 4.28	25 (22-28); 24.98 ± 4.35	25	195.9	0.001	Baseline-1 mo; Baseline-3 mo; Baseline-6 mo; 1-3 mo; 1-6 mo; 3-6 mo
	Control (n = 98)	19 (17-22); 19.64 ± 3.73	20 (17-22); 19.50 ± 3.67	20 (17-22); 19.50 ± 3.67	20 (17-22); 19.45 ± 4.03	5	24.43	0.001	Baseline-6 mo; 1-6 mo; 3-6 mo; 3-1 mo; 3 mo-Baseline; 1 mo-Baseline
Anxiety	Experimental (n = 97)	36 (27-41); 34.65 ± 7.85	29 (24-39); 30.55 ± 7.50	25 (21-32); 26.81 ± 7.68	19 (15-26); 21.82 ± 8.57	47	237.3	0.001	6-3 mo; 6-1 mo; 6 mo-Baseline; 3-1 mo; 3 mo-Baseline; 1 mo-Baseline
	Control (n = 98)	35 (30-42.5); 36.69 ± 9.36	34.50 (29-45); 37.01 ± 10.33	31 (26-46); 35.13 ± 11.23	28.50 (22-45); 33.02 ± 12.43	19	31.9	0.001	6-3 mo; 6-1 mo; 6 mo-Baseline; 3-1 mo; 3 mo-Baseline; Baseline-1 mo
Depression	Experimental (n = 97)	13 (9.50-17); 13.30 ± 5.56	12 (9-15); 12.14 ± 5.03	9 (6-13); 10 ± 5.05	8 (4-10); 7.58 ± 4.71	38	243.5	0.001	6-3 mo; 6-1 mo; 6 mo-Baseline; 3-1 mo; 3 mo-Baseline; 1 mo-Baseline
	Control (n = 98)	12 (9-17); 12.86 ± 5.34	10 (7-16); 11.47 ± 5.44	10.50 (6-6.25); 11.19 ± 6.34	10 (6.75-18); 11.47 ± 6.55	17	48.9	0.001	6 mo-Baseline; 3-1 mo; 3 mo-Baseline; 1 mo-Baseline; 3-6 mo; 1-6 mo

^a P < 0.05 was significant.